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demographic characteristics, total health care utilization and cost burden were
higher for patients who suffered a TIA after an NVAF diagnosis, relative to patients
who did not.
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OBJECTIVES: To compare clinical outcomes and cost burden of patients who suf-
fered a stroke during the 180 days after diagnosis of non-valvular atrial fibrillation
(NVAF) with patients who did not. METHODS: Based on 2005-2007 US Medical
insurance claim files, patients aged 65 years and older who have had two or more
primary diagnoses of NVAF, occurring within 30 days of one another, were selected.
The 180-day follow-up mortality rate, health care facility use and costs for patients
with and without incidences of stroke were compared. Risk adjustment was per-
formed using the propensity score matching (PSM) method with the ProbChoice™
algorithm. RESULTS: Out of patients who were identified with and without NVAF
pre-stroke (n18,195), 541 (2.97%) suffered a stroke during the 180 days after the
NVAF diagnosis. After PSM risk-adjustment for pre-specified covariates, mortality
(7.39% vs. 1.07% p0.0001), outpatient emergency room (ER) visits (80.59% vs.
48.11% p0.0001), readmission rates (1.85% vs. 0.40%, p0.0001), transient isch-
emic attacks (44 vs. 8 /100 person years), and intracranial hemorrhage rates (71 vs.
7/100 person years) were all higher for patients who suffered a stroke compared to
those who did not. Although risk-adjusted outpatient ER costs and office visit costs
did not differ significantly between the two groups, patients who suffered a stroke
had significantly higher inpatient ($24,231 vs. $15,137, p0.0001) and total ($33,439
vs. $13,782, p0.0001) expenditures. CONCLUSIONS: Most of the adverse events
analyzed were higher for patients who suffered a stroke after an NVAF diagnosis
relative to patients who did not. Total health care utilizations and health care costs
were also significantly increased.
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OBJECTIVES: To ascertain the direct costs related to hospitalization in the Physical
Medicine Service and Rehabilitation of a tertiary referral hospital during the year
2009. METHODS: An epidemiological, observational retrospective study was car-
ried out in the Central University Hospital of Asturias –HUCA-, Spain. All patients
admitted to the Rehabilitation Unit (RU) and suffering from a cerebrovascular dis-
ease (CVD), brain injury (BI), spinal cord injury (SCI) or amputations were included.
RU services was acting as secondary referral level -SRL- in case of BI and CVD. In
contrast, SCI and amputations were attended in the same RU as tertiary referral
level-TRL-. A cost-analysis following hospital perspective was performed recording
all health resources at patient level. Next, direct costs were calculated attaching a
published cost to each resource. Socio-demographic and clinical variables were
registered to describe the sample and to facilitate external comparisons. Mean
costs per patient were calculated considering each of the pathologies and compar-
ing SRL and TRL. Costs were defined in 2009 Euros. Chi2 test was used to compare
socio-demographic and clinical variables between groups. Next, parametric (Stu-
dent’s t test and ANCOVA analysis) and non parametric analysis (bootstrapping)
were applied to estimate economic differences between groups. RESULTS: A total
of 243 patients admitted to RU were assessed. Mean age (SD) was 59.62 years (1.41)
and 71.2% males. Mean cost per patient (SD): BI(n 15) 28,837.87(23,998.80); CVD(n
116), 31,751.05(19,151.26); SCI(n 105), 27,635.39(24,856.55); amputations(n 7),
24,342.86(5,426.48). Mean SRL cost was significantly higher than TRL:
31,417.48(19,681.03) and 27,429.61(24,106.37), respectively (p 0.013). Total anual
SRL cost was 4,115,751.43 and 3,072,167.39 TRL. CONCLUSIONS: Forty-six percent
of total activity in the RU is related to TRL requiring 43% of total expenditure.
Further research comparing this policy with early discharge and home rehabilita-
tion should be implemented to promote the efficiency of this service.
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OBJECTIVES: Atrial fibrillation (AF) is a prevalent disease that often requires costly
hospital care, but the cost of hospital utilization has not been reported in Canada.
The purpose of this study was to estimate the cost of hospital utilization for AF in
Canada. METHODS: Three national administrative databases (Discharge Abstract
Database, Same Day Surgery and National Ambulatory Care Reporting System) for
the year 2007/08 were used to capture admissions, same day surgeries and emer-
gency department (ED) visits. Provincial/territorial data were extrapolated to the
national level using age-gender census information where necessary. Records with
a most responsible diagnosis (MRD) of AF, atrial flutter or a secondary diagnosis of
AF were included in the analysis. Hospital costs were estimated by applying an
average cost per weighted case to the resource intensity weight that was provided
for each admission/visit, and then adding the physician fees for admissions, sur-
geries and interventions. All cost estimates are expressed in 2010 Canadian dollars.
RESULTS: In 2007/08, the number of hospital admissions with MRD of AF was
10,924 for men and 11,899 for women, same day surgeries was 3,910 for men and
1,797 for women and ED visits were 29,754 for men and 28,312 for women. The
average cost per admission was $6,718 with an average length of stay of 5.7 days.
The average cost of same day surgery was $3,524 and an ED visit was $849. The total
hospital cost for patients with AF was $815M; $710M for hospital admissions,
$72.9M for ED visits, and $31.8M for same day surgery. Most of the costs were for
hospital admissions when AF was listed as a comorbidity ($558.2M, 69%)
CONCLUSIONS: The substantial cost burden of AF in the acute care sector is driven
by the consequences of AF, while the costs for specific treatments for AF are rela-
tively low.
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OBJECTIVES: Acute coronary syndrome (ACS) is the most important clinical con-
sequence of coronary artery disease and a leading cause of death worldwide. This
study aims to assess the costs of ACS from a social and health insurance perspec-
tive evaluating direct costs, production losses and intangible costs in terms of
quality adjusted life years (QALYs) lost. METHODS: A bottom-up incidence ap-
proach was used. ACS-Patients with one or more ACS events were extracted from
a national hospital database and from mortality statistics. Remaining life years of
surviving patients were modelled on age, gender and life expectancy statistics.
Inpatient costs include acute care and rehabilitation in 2008. Outpatient costs in-
clude costs for ambulance, visits to GP and cardiologist, outpatient diagnostics,
medication and rehabilitation. Production losses were calculated according to the
human capital approach, including absenteeism, permanent disability and prema-
ture death. Intangible costs were calculated based on literature data. Cost data are
derived from official price lists, literature and experts. Validation of clinical data
was conducted using the AMIS-PLUS registry. RESULTS: A total of 14,955 patients
experienced a total of 16,815 ACS events in 2008; 2,752 died as a consequence of
these. This resulted in 19,064 hospital stays with an average length of stay in acute
care of 8.9 days per patient. Total direct costs amounted to 690 Mio Swiss Francs
(CHF) for the society and 523 Mio CHF for health insurers. Forty-four percent belong
to inpatient and 56% to outpatient services. Production losses were 515 Mio. CHF
and intangible costs resulted in 37,457 QALYs lost. Average total direct costs and
production losses per patient were 80,873 CHF. Results appear robust in sensitivity
analysis. CONCLUSIONS: ACS causes considerable costs in terms of direct medical
expenditures, lost production and premature death, even without taking into ac-
count costs for its chronic consequences such as congestive heart failure.
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OBJECTIVES: Atrial fibrillation (AF) is the commonest cardiac arrhythmia found in
clinical practice with an increasing prevalence in the aging population. Local esti-
mates vary from 1.2 to 2.5%. The objective of our study was to evaluate the burden
of AF on secondary care costs in England, which is responsible for substantial
cardiovascular morbidity and mortality. METHODS: AF and stroke event and cost
data captured in Hospital Episode Statistics(HES), between 2006 and 2009, was
analysed to estimate the trends in hospital episodes in England. RESULTS: A total
of 193,742 patients with a primary or secondary diagnosis of AF were hospitalised
in 2009, representing a 19% increase in AF patients on the previous 3 years. During
this period there were 239,746 hospital spells with a diagnosis of AF; a 22% increase
from 2006-2009. The total inpatient cost attributable to AF increased from £353
million in 2006 to a total of £361 million in 2009. As a proportion of all admissions,
AF admissions were 1.1% in 2006 to 1.2% in 2009 and represented 1,162,213 bed days
occupied in 2006 versus 1,108,283 in 2009. In 2009, of the 193,742 patients with a
diagnosis of AF, 5,391 subsequently had a stroke. This gives a conversion rate from
AF to stroke of 3.1% of patients – up from 2.5% in 2006. During this same period, the
average length of stay for the stroke patient with AF has increased from 38 days to
43 days (higher than those patients who have only had a stroke). CONCLUSIONS:
Despite advances in both AF and stroke management, AF presents a significant and
increasing burden on hospital care in England. New initiatives are needed to detect
AF early and prevent hospital admissions or to manage AF in rapid access arrhyth-
mia clinics where appropriate therapies to manage the rate, rhythm and cardio-
vascular risks can be dispensed without needing admission.
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OBJECTIVES: The objective of this study was to quantify, for the first time in a
Spanish population, the time and cost burden of informal care for pts with heart
failure. METHODS: A descriptive analysis of a multicenter, prospective observa-
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tional study was performed. Pts who met inclusion criteria were followed-up for 12
months, with 3 visits programmed at baseline, 6 and 12 months. Baseline charac-
teristics and caregiver’s information were registered for every pt. Once identified
total hours, the replacement cost method was used. RESULTS: A total of 330 pt
were included, 74.2% men, mean age was 62.9 years. 82.4% were in NYHA class II,
16.4% NYHA class III and 1.2% NYHA class IV. A 28.5% needed support for daily
living. Ninety four informal caregivers were identified, mean age of 58yo, mostly
women (85.1%). Main relationship with caregiver was spouse/couple (77.7%), fol-
lowed by son/daughter (14.9%). Number of weekly hours of main caregiver was
estimated at 44.3 hours (40.6 hours for patients NYHA class II and 53.3 hours for
patients NYHA class III-IV) and shadow prices values from 8-13€/hour. Total costs
associated to informal caregiving increased between €21,298-€34,609 per pt of
which between €18,892-€30,049 are informal costs associated with the main care-
givers. Likewise, focusing on main caregivers, using the proxy-good method and
the shadow prices shown, the cost of replacing services by care giving a Class II
patient (2,115 yearly hours) were between €16,919-€27,494 for pts in NYHA class II;
and between €22,230-€36,123 for caregiving a Class III or IV pt (2,779 yearly hours).
CONCLUSIONS: Almost a 30% of pts with chronic symptomatic HF in Spain re-
quired support from an informal caregiver, which represents a significant burden
for society and often has not been accounted for in economic evaluations of treat-
ments for heart failure. Costs for informal care are associated with disease severity
as measured by NYHA class.
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OBJECTIVES: To evaluate the first-year direct medical cost for diagnosis and man-
agement of newly diagnosed SA, to identify SA-related resource consumption pat-
tern in public hospitals in the New Territories East Cluster in Hong Kong and in
patients with and without procedures, and with comorbidities of hypertension
(HTN), diabetes mellitus (DM) and hyperlipidemia.METHODS:A retrospective non-
randomized study was conducted including patients documented with new diag-
nosis of SA in the Clinical Management System during January 2007 to December
2009. Subjects were followed for 1 year after diagnosis. Cost items studied con-
sisted of hospitalization, clinic visits, diagnostic tests, radiological examinations,
laboratory tests, therapeutic operations and medications. For statistical analyses,
Mann-Whitney Tests were performed to compare medians of costs in patients with
and without procedures, and with different comorbidities of HTN, DM and hyper-
lipidemia. P-value 0.05 was regarded significant. RESULTS: 89 patients were re-
cruited. The mean first-year total direct medical cost of SA per patient was
HKD$89,518, with the cost for hospitalization being the most dominant, accounting
for 29.2%. Increase in complexity of disease would increase the total from
HKD$47,744 for patients without procedures to HKD$115,342 for patients with pro-
cedures (p0.001). For the three comorbidities interested, SA patients co-morbid
with hyperlipidemia required more resources for the management, HK$98,295
(p0.001).CONCLUSIONS:This study revealed the huge expenses incurred by SA in
the first year of initial diagnosis on local public healthcare system, which has a
significant implication on future resources allocation. Strategies for cost saving
and preventive measures should be implemented.
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OBJECTIVES:Dysphagia commonly occurs following stroke and contributes to sub-
sequent morbidity and mortality in stroke survivors with related substantial eco-
nomical implications. Literature on the burden of this medical condition is scarce.
This study aimed to identify the reported burden of dysphagia among stroke
patients. METHODS: Epidemiological data were collected from publications in
stroke and/or dysphagic patients and included prevalence of dysphagia and pneu-
monia, as its main complication. Economical data mainly included hospital length
of stay, and pneumonia treatment costs. RESULTS: The data demonstrate stroke
mostly occurs in people older than 65 years age (75%). Prevalence and epidemio-
logical figures varied widely from one publication to another. Indeed, up to 81% of
stroke patients were diagnosed as dysphagic, depending on the method and time
after stroke episode in which dysphagia is identified. Thus reportedly, up to 19.6
million stroke patients suffer dysphagia in North America and Europe. Studies
identified that 40% to 50% of dysphagic stroke patients aspirate. In addition, pneu-
monia occurs in up to 51% of dysphagic stroke patients. Of course, dysphagic stroke
patients who aspirate are at higher risk of pneumonia: up to 11-fold more than non
aspirators. In Europe and North America, up to more than 10 million dysphagic
stroke patients develop pneumonia. Furthermore hospital length of stay ranges
from 5.07 to 10.55 days for stroke patients with dysphagia versus 3.26 to 4.74 days
without dysphagia. The average hospital cost for pneumonia is $919 per day, total-
ing up to $96.5 billion in Europe and North America. CONCLUSIONS: The overall
dysphagia burden is substantial worldwide, especially in Europe and North Amer-
ica. It is probably underestimated since only direct medical costs were included.
However, it will most probably increase given the growing elderly population,
which is at higher risk of having stroke.
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OBJECTIVES: The aim of the present study is to estimate the annual direct and
indirect costs in patients with a history of or at risk for atherothrombosis in Greece,
using a bottom-up approach. METHODS: A multicentre, prospective, cost-of-ill-
ness study was conducted between January 2007 and December 2009. In this study,
800 patients with coronary artery disease (CAD) or cerebrovascular disease (CD) or
peripheral artery disease (PAD) or multiple cardiovascular risk factors (MRF) were
recruited from 11 major hospitals in Greece. All patients were followed up for 12
months. Resources used for the care of patients within the healthcare system and
productivity losses during the follow-up period were recorded. The annual direct
and indirect costs were calculated by combining these data with unit costs.
RESULTS: The mean annual total cost was €5,940/patient (€5,416–€6,522). This cost
ranges from €9,963/patient (€8,515–€11,868) for PAD group to €1,761/patient (€1,462–
€2,232) for MRF group. The mean annual direct healthcare cost was €5,056 /patient
(€4,653–€5,507). This cost escalates from €1,623 /patient (€1,319– €2,073) for MRF
group to € 8,697 /patient (€7,648– €9,695) for PAD group. The annual direct health-
care costs was mainly driven by vascular intervention costs among CAD and PAD
patients, (50.6% and 46.5%, respectively) and by the simple hospitalization cost
among CD and MRF patients (67.7% and 35.7%, respectively). The mean annual
indirect cost was €979 (€386– €1,395), €441 (€142- €835), €525 (€148 – €1,137) and €29
(€1- €87) per patient in the CD, CAD, PAD and MRF groups, respectively. The total
annual expenditures related to atherothrombosis, in Greece, are estimated to be 7.5
billion € at a national level. CONCLUSIONS: The findings of the THESIS study indi-
cate, for the first time, the high economic burden of atherothrombosis in Greece,
since the direct healthcare cost related to atherothrombosis management ac-
counts for almost 25% of annual healthcare expenditures.
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OBJECTIVES: Atrial fibrillation (AF) is the most common arrhythmia in clinical
practice and associated with a high risk of stroke. In Austria, about 130,000 people
are affected by AF. The first aim was to create a patient flow with epidemiological
data to close the research gap for Austria and further to estimate the total cost of
patients (direct and indirect costs) with AF and recommended oral anticoagulation.
METHODS: The model is based on these detected AF patients. The approach used
is prevalence-based, which is usually forgone within the time horizon of one year.
For 68% of these patients oral anticoagulation is recommended, but only 54% of
patients in the high-risk group received an OAC therapy. The remaining patients
get Aspirin (31%), other medication (5%) or no therapy (10%). Clinical-data and costs
of the adverse events stroke and major bleeding were considered. Direct costs
comprise all direct medical costs like consultation, lab test, inpatient costs, medi-
cation and treatment costs. Indirect costs represents costs for AF patients after
stroke like care allowance and costs of nursing homes. The resource use was de-
termined by literature and experts. All costs represent data from 2011. The burden
of disease study is conducted from a societal perspective. RESULTS: The direct
costs of AF patients amount to 51,972,668€ and the total costs inclusive indirect
costs are 93,915,299€ for the time horizon of one year. CONCLUSIONS: With rising
life expectancy the number of patients with AF and the prevalence of strokes will
increase. Therefore the time has come to give greater attention to the epidemio-
logical and socioeconomic burden of AF.
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OBJECTIVES: Interactions of mental illnesses and heart failure have been indi-
cated. Mental illness has been shown to be a risk factor of heart failure. In addition,
it may worsen the symptoms as well as compliance to the therapy of patients with
heart failure. A recent study has showed that comorbid depression may be associ-
ated with higher medical costs. The purpose of this study was to assess the impact
of comorbid mental illness on costs of health care for inpatients with heart failure.
METHODS: A retrospective cohort study of inpatients with heart failure. Data were
collected between July 1, 2008, and December 31, 2008 from 855 acute care hospitals
in Japan. In total, 38,446 admissions of patients with heart failure in 855 hospitals
were included in the analysis. We compared health care costs of 5 groups: 1) no
mental illness; 2) antidepressant prescription only; 3) co-prescription of antide-
pressant and other psychotropic drugs; 4) antidepressant prescription and depres-
sion diagnosis recorded; and 5) anxiolytic or hypnotic prescription only. Statistical
analyses were performed using JMP 8.0. RESULTS: Psychotropic drugs were used in
19,839 (51.6%) patients with heart failure. The average number of psychotropic
drugs was 3.69 per hospitalization in heart failure inpatients. After adjustment for
covariates, patients prescribed with psychotropic drugs had significantly higher
costs than patients not prescribed. CONCLUSIONS: This study suggested that co-
morbid mental illness is associated with higher medical costs.
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